Analyst Rating Update on Dicerna Pharmaceuticals (DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) has an average broker rating of 1.4, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Dicerna Pharmaceuticals (NASDAQ:DRNA) : Average target price received by Dicerna Pharmaceuticals (NASDAQ:DRNA) is $14.5 with an expected standard deviation of $6.46. The most aggressive target on the stock is $19, whereas the most downbeat target is $5. 4 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Chardan Capital initiates coverage on Dicerna Pharmaceuticals (NASDAQ:DRNA). The current rating of the shares is Neutral, according to the research report released by the firm. The brokerage firm announces the price target at $5 per share. The rating by the firm was issued on April 4, 2016.

Dicerna Pharmaceuticals (NASDAQ:DRNA): stock turned positive on Tuesday. Though the stock opened at $2.82, the bulls momentum made the stock top out at $3.5 level for the day. The stock recorded a low of $2.7101 and closed the trading day at $3.16, in the green by 17.04%. The total traded volume for the day was 2,287,512. The stock had closed at $2.7 in the previous days trading.

Dicerna Pharmaceuticals, Inc. (Dicerna) is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNA interference (RNAi) technology platform to build a pipeline in these therapeutic areas. The Company is in collaboration with two companies for oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. (KHK). Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1), Additional Liver Targets, DCR-MYC for MYC-related cancers and KRAS Program. Dicernas discovery approach is based on double-stranded RNA molecules, called Dicer Substrate siRNA (DsiRNA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *